BioAge Labs (NASDAQ:BIOA) Shares Up 8.8% – Still a Buy?

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) were up 8.8% during trading on Monday . The company traded as high as $20.37 and last traded at $20.37. Approximately 82,282 shares were traded during trading, a decline of 89% from the average daily volume of 752,611 shares. The stock had previously closed at $18.72.

Analyst Ratings Changes

Several analysts have recently weighed in on BIOA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, January 27th. Morgan Stanley set a $23.00 price objective on BioAge Labs in a report on Wednesday, February 4th. Oppenheimer began coverage on BioAge Labs in a research report on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price objective for the company. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Finally, Citigroup upped their price target on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $45.00.

BioAge Labs Trading Down 1.5%

The stock has a market capitalization of $760.74 million, a price-to-earnings ratio of -13.96 and a beta of 1.22. The firm’s fifty day moving average price is $19.94 and its 200 day moving average price is $12.34.

Insider Buying and Selling at BioAge Labs

In other news, insider Paul D. Rubin sold 7,433 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total transaction of $139,368.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kristen Fortney sold 233,107 shares of BioAge Labs stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total value of $4,223,898.84. Following the completion of the sale, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 267,540 shares of company stock valued at $4,895,168 over the last quarter. 20.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of BIOA. Vanguard Group Inc. increased its stake in BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after purchasing an additional 93,694 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of BioAge Labs in the fourth quarter valued at approximately $13,892,000. Geode Capital Management LLC boosted its stake in shares of BioAge Labs by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock valued at $7,826,000 after purchasing an additional 28,646 shares during the period. State Street Corp grew its holdings in shares of BioAge Labs by 113.4% in the fourth quarter. State Street Corp now owns 422,846 shares of the company’s stock valued at $5,594,000 after purchasing an additional 224,735 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in BioAge Labs during the 4th quarter worth approximately $5,406,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.